Search Results for "A-200"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for A-200. Results 311 to 320 of 660 total matches.

Extended-Release Minocycline (Solodyn) for Acne

   
The Medical Letter on Drugs and Therapeutics • Nov 20, 2006  (Issue 1248)
mg, and those >200 pounds, 135 mg. 96 The Medical Letter • Volume 48 • Issue 1248 ...
The FDA has approved an extended-release formulation of minocycline (Solodyn - Medicis) for once-daily treatment of non-nodular moderate to severe acne.
Med Lett Drugs Ther. 2006 Nov 20;48(1248):95-6 |  Show IntroductionHide Introduction

A Fixed-Dose Combination of Sumatriptan and Naproxen for Migraine

   
The Medical Letter on Drugs and Therapeutics • Jun 16, 2008  (Issue 1288)
) is available over the counter (OTC). The NSAID ibuprofen in a dose of 200 mg (Advil, and others) is FDA ...
The FDA has approved an oral, fixed-dose combination (Treximet - GlaxoSmithKline) of the selective serotonin receptor agonist ("triptan") sumatriptan (Imitrex) and the nonsteroidal anti-inflammatory drug (NSAID) naproxen sodium (Anaprox, and others) for acute treatment of migraine attacks.
Med Lett Drugs Ther. 2008 Jun 16;50(1288):45-6 |  Show IntroductionHide Introduction

Armodafinil (Nuvigil) for Wakefulness

   
The Medical Letter on Drugs and Therapeutics • Aug 09, 2010  (Issue 1344)
Dosage1 Cost2 Armodafinil 50, 150, 250 mg 150 mg $349.20 Nuvigil tabs (Cephalon) Modafinil – 100, 200 ...
Armodafinil (Nuvigil – Cephalon), the R-enantiomer of the non-amphetamine stimulant modafinil (Provigil – Cephalon; Alertec – Shire in Canada), is being promoted directly to the public for treatment of excessive daytime sleepiness associated with shift work.
Med Lett Drugs Ther. 2010 Aug 9;52(1344):61-2 |  Show IntroductionHide Introduction

COVID-19 Updates

   
The Medical Letter on Drugs and Therapeutics • Feb 21, 2022  (Issue 1644)
with remdesivir (200 mg on day 1 and 100 mg on days 2 and 3) or placebo. Hospitalization related to COVID-19 ...
The IV antiviral drug remdesivir (Veklury – Gilead) has been available for treatment of COVID-19 in hospitalized patients since 2020. Now, the FDA has approved remdesivir for treatment of mild to moderate COVID-19 in outpatients ≥12 years old who weigh ≥40 kg and are at high risk for progression to severe disease, including hospitalization or death; they also issued an Emergency Use Authorization (EUA) allowing its use in any other high-risk outpatient who weighs ≥3.5 kg.
Med Lett Drugs Ther. 2022 Feb 21;64(1644):31-2 |  Show IntroductionHide Introduction

Comparison Table: Some Drugs for Postmenopausal Osteoporosis (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 08, 2024  (Issue 1706)
Calcitonin Calcitonin – generic 200 IU/spray (3.7 mL bottle) Not approved 200 IU intranasally once/day ...
View the Comparison Table: Some Drugs for Postmenopausal Osteoporosis
Med Lett Drugs Ther. 2024 Jul 8;66(1706):e112-4   doi:10.58347/tml.2024.1706b |  Show IntroductionHide Introduction

Drugs for Depression

   
The Medical Letter on Drugs and Therapeutics • Dec 11, 2023  (Issue 1691)
25, 50, 100, mg tabs; 150, 50 mg once/day 50-200 mg once/day 2.90 Zoloft (Pfizer) 200 mg caps; 20 ...
A selective serotonin reuptake inhibitor (SSRI) is generally used for initial treatment of major depressive disorder (MDD). A serotonin-norepinephrine reuptake inhibitor (SNRI), bupropion (Wellbutrin SR, and others), and mirtazapine (Remeron, and others) are reasonable alternatives. Improvement in symptoms can occur within the first two weeks of treatment with these drugs, but a substantial benefit may not be achieved for 4-8 weeks.
Med Lett Drugs Ther. 2023 Dec 11;65(1691):193-200   doi:10.58347/tml.2023.1691a |  Show IntroductionHide Introduction

Cefiderocol (Fetroja) - A New IV Cephalosporin for Complicated UTI

   
The Medical Letter on Drugs and Therapeutics • May 04, 2020  (Issue 1597)
vials; 1, 2 g/50 mL bags Fluoroquinolones Ciprofloxacin – generic 200 mg/20 mL, 400 mg/40 mL vials ...
The FDA has approved cefiderocol (Fetroja – Shionogi), a new IV cephalosporin antibiotic, for treatment of complicated urinary tract infections (UTI) caused by susceptible gram-negative bacteria in adults who have limited or no alternative treatment options.
Med Lett Drugs Ther. 2020 May 4;62(1597):65-8 |  Show IntroductionHide Introduction

Nirsevimab (Beyfortus) for Prevention of Severe RSV Disease in Young Children

   
The Medical Letter on Drugs and Therapeutics • Sep 18, 2023  (Issue 1685)
a 200-mg dose of nirsevimab or the same dose of palivizumab in their second RSV season; there were ...
The FDA has approved nirsevimab-alip (Beyfortus – AstraZeneca/Sanofi), a long-acting monoclonal antibody, for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants born during or entering their first RSV season, and in children ≤24 months old who are at increased risk for severe RSV disease through their second RSV season. Nirsevimab is the first drug to be approved for protection of all infants during their first RSV season.
Med Lett Drugs Ther. 2023 Sep 18;65(1685):145-7   doi:10.58347/tml.2023.1685a |  Show IntroductionHide Introduction

Lebrikizumab (Ebglyss) for Atopic Dermatitis

   
The Medical Letter on Drugs and Therapeutics • Nov 11, 2024  (Issue 1715)
Abrocitinib – Cibinqo (Pfizer) 50, 100, 200 mg tabs 100 mg PO once/day2 $5567.30 Baricitinib – Olumiant ...
The FDA has approved lebrikizumab-lbkz (Ebglyss – Lilly), a subcutaneously injected interleukin (IL)-13 antagonist, for treatment of moderate to severe atopic dermatitis that has not been or cannot be adequately treated with topical therapy in patients ≥12 years old (weight ≥40 kg). Lebrikizumab is the third subcutaneously injected human IgG4 monoclonal antibody to be approved in the US for this indication. Tralokinumab (Adbry), another IL-13 antagonist, is also approved for use in patients ≥12 years old, and dupilumab (Dupixent), an IL-4 and IL-13 inhibitor, is approved for...
Med Lett Drugs Ther. 2024 Nov 11;66(1715):179-81   doi:10.58347/tml.2024.1715b |  Show IntroductionHide Introduction

Acesulfame - A New Artificial Sweeteners

   
The Medical Letter on Drugs and Therapeutics • Dec 16, 1988  (Issue 781)
is soluble in water and stable at temperatures up to about 225° C. The sweetness of acesulfame is 200 times ...
Acesulfame potassium (Sunette - Hoechst), an oxathiazinondioxide, was recently approved by the US Food and Drug Administration (FDA) for use as a non-caloric table-top sweetener and as an ingredient in chewing gum, powdered beverages, gelatins and puddings. The other non-caloric artificial sweeteners available in the USA are saccharin (Sweet 'N Low; and others) and aspartame (NutraSweet; Equal) (Medical Letter, 24:1, 1982).
Med Lett Drugs Ther. 1988 Dec 16;30(781):116 |  Show IntroductionHide Introduction